Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Regulatory plan for certification of a novel tuberculosis diagnostics

Reference number
Coordinator Nornir Labs AB
Funding from Vinnova SEK 199 000
Project duration May 2026 - June 2027
Status Ongoing
Venture Medtech4Health: Competence Enhancement in SME
Call Medtech4Health: Competence Enhancement in Small Businesses, spring 2026

Purpose and goal

Nornir Labs´s first diagnostic product is an antibiotic susceptibility test for tuberculosis bacteria, from samples taken from sick patients, where we aim to shorten the response time from weeks with existing methods, down to one day with our test. The purpose of this project is to develop a regulatory plan for product approval and launch.

Expected effects and result

An understanding of similarities and differences in regulatory risk class, validation and trial time between Europe and countries in Asia and Africa. When complete, we will have an overall regulatory timeline for submission in countries where drug-resistant tuberculosis is a real problem.

Planned approach and implementation

We have developed questions to answer together with an expert consultant. The focus is on quality systems and regulatory strategy. We will also bring in knowledge from experts in each country being investigated.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 9 June 2026

Reference number 2026-00576